Research Paper Volume 12, Issue 3 pp 2992—3009

Figure 5. EGF derived from hPMSCs suppressed ROS in POI hGCs. (A) hPMSC, hPMSC-CM or EGF treatment suppressed ROS in vitro to normal levels (POI hGCs). (B) ELISA results revealed that hPMSCs, hPMSC-CM or EGF treatment inhibited MDA expression to the WT group level. (C) hPMSC, hPMSC-CM or EGF treatment suppressed the level of SOD expression in vitro. (D) ELISA results indicated that hPMSCs, hPMSC-CM or EGF treatment elevated CAT expression in POI hGCs. (E) hPMSC, hPMSC-CM or EGF treatment increased LDH expression to the WT group level in vitro. (F) ELISA results demonstrated that hPMSCs, hPMSC-CM or EGF improved the level of GR in vitro. (G) hPMSC, hPMSC-CM or EGF treatment increased GPx expression to normal levels in POI hGCs. All of the experiments were carried out three times. The error bars indicate the SD; *** p < 0.001 (compared with the POI group). POI = premature ovarian insufficiency.